Lenacapavir by Gilead demonstrates 96% reduction in HIV infections in clinical trial.

A recent study has shown that Gilead’s new HIV prevention injectable drug, lenacapavir, has proven to reduce HIV infections by 96%. This positive phase-three trial data indicates the potential approval

Detail